Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Lowered by Oppenheimer

Oppenheimer cut shares of Nektar Therapeutics (NASDAQ:NKTR – Get Rating) from an outperform rating to a market perform rating in a research note published on Monday, The Fly reports. Oppenheimer also issued estimates for Nektar Therapeutics’ FY2022 earnings at ($2.94) EPS, FY2023 earnings at ($2.49) EPS, FY2024 earnings at ($2.22) EPS and FY2025 earnings at […]

Related Keywords

Louisiana ,United States ,America ,Stifel Nicolaus ,Howardw Robin ,Gilm Labrucherie ,William Blair ,Jpmorgan Chase Co ,First Citizens Bank Trust Co ,Nektar Therapeutics ,Nektar Therapeutics Company Profile Get Rating ,Ieq Capital ,Berman Capital Advisors ,Nasdaq ,Get Rating ,Nektar Therapeutic ,State Employees Retirement System ,Capital Management ,Citizens Bank ,Capital Advisors ,Therapeutics Company Profile ,Nasdaq Nktr ,Nktr ,Medical ,64026810 ,Downgrade ,Oppenheimer Holdings Inc ,